December 01, 2025 a 08:00 am
GILD: Fundamental Ratio Analysis - Gilead Sciences, Inc.
Gilead Sciences, Inc. operates in a competitive biopharmaceutical market, focusing on unmet medical needs globally. The company's diverse product portfolio and strategic partnerships position it well for future growth. However, factors such as competitive pressure and regulatory challenges could impact its market performance.
Fundamental Rating
Gilead Sciences received a fundamental rating of A-, indicating strong financial health and growth potential.
| Metric | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return On Equity | 5 | |
| Return On Assets | 5 | |
| Debt To Equity | 2 | |
| Price To Earnings | 2 | |
| Price To Book | 1 |
Historical Rating
The following table showcases the stability of Gilead Sciences' financial metrics over time.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-12-01 | 4 | 5 | 5 | 5 | 2 | 2 | 1 |
| 2025-11-28 | 4 | 5 | 5 | 5 | 2 | 2 | 1 |
Analyst Price Targets
Analysts have assigned the following price targets to Gilead Sciences' stock, reflecting their optimism about its potential upside.
| High | Low | Median | Consensus |
|---|---|---|---|
| 147 | 105 | 135 | 130.4 |
Analyst Sentiment
The sentiment among analysts is predominantly positive with a consensus recommendation to buy.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 36 | |
| Hold | 20 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Gilead Sciences demonstrates consistent financial strength, reflected in its high scores in discounted cash flow and return metrics. While its debt to equity ratio and price valuation metrics may raise some concern, the overall confidence in its stock, signaled by analysts' buy ratings, suggests a positive outlook. The company's broad product portfolio in critical disease areas offers significant growth opportunities, though industry competition remains a risk. Investors may find value in Gilead's innovative R&D and global reach, while closely monitoring potential regulatory shifts. Overall, its strategic partnerships and collaboration agreements enhance its long-term prospects.